Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Feels Statistical Pain, Withdraws Cymbalta sNDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will resubmit the application for chronic pain in 2009 along with a recently completed study using FDA’s preferred analysis for patient drop outs.

You may also be interested in...



Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

Patient Dropouts, Other “Missing Data” To Be Addressed In FDA Guidance

FDA hopes two guidances - one on non-inferiority margins and another on how to handle missing data in clinical trials - will better direct industry in developing clinical trials and extrapolating more accurate data

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel